MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00868595 |
|
Recruitment Status :
Completed
First Posted : March 25, 2009
Last Update Posted : October 8, 2019
|
Sponsor:
Bellicum Pharmaceuticals
Collaborators:
M.D. Anderson Cancer Center
The University of Texas Health Science Center, Houston
Memorial Hermann Hospital
Baylor College of Medicine
Information provided by (Responsible Party):
Bellicum Pharmaceuticals
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | July 2011 |
| Actual Study Completion Date : | March 2012 |